Relative effectiveness assessment systems are new, complex, and set to shape the future requirements for drug makers seeking reimbursement for new therapies in Europe.
Developing clinical trial data necessary for reimbursement dossiers is a costly process, and the information needs of regulators, reimbursement authorities, and payers are often very different.
This leaves pharmaceutical companies unclear on what are the best types of data to develop in order to secure reimbursement across multiple markets.
A New Study from IHS Global Insight
Our latest study The New REAlity of Relative Effectiveness: An International Comparison of Evolving Requirements, explores the types of data payers are willing to consider to approve and set reimbursement levels for a given drug.
The study will provide an invaluable resource to help pharma companies get their clinical trial data right the first time.
Answering Your Key Questions
Using primary research of payers in the United States, Canada, Australia, Germany, France, Italy, and the United Kingdom, the study will answer the following key questions:
- What clinical trial endpoints do payers want to see in order to inform their decision-making?
- How is Relative Effectiveness Assessment (REA) situated within the broader reimbursement decision-making process in each market?
- How is the use of REA evolving in this context within each market?
- Do payers value Patient Reported Outcomes (PROs) and does this vary by therapeutic area?
- What clinical trial designs best address payer information needs? How are the appropriate therapeutic comparators selected in each market?
- How do payers' clinical trial endpoint requirements vary by therapeutic area?
- How can markets be segmented, given the above information, in terms of market access strategy?